Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: north american brain tumor consortium study 04-03

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 6032-6039

  Lee, Eudocia Q ^a   Puduvalli, Vinay K ^b   Reid, Joel M ^c   Kuhn, John G ^d   Lamborn, Kathleen R ^e   Cloughesy, Timothy F ^f   Chang, Susan M ^e   Drappatz, Jan ^a,g   Yung, W K Alfred ^b   Gilbert, Mark R ^b   Robins, H Ian ^h   Lieberman, Frank S ^g   Lassman, Andrew B ⁱ   McGovern, Renee M ^c   Xu, Jihong ^b   Desideri, Serena ^j   Ye, Xiabu ^j   Ames, Matthew M ^c   Espinoza Delgado, Igor ^k   Prados, Michael D ^e   Wen, Patrick Y ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H4; TEMOZOLOMIDE; VORINOSTAT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HEMATOMA; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOMA; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASM GRADING; TREATMENT OUTCOME;

EID: 84868561843     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1841     Document Type: Article

References (14)

1. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
2. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009;2:31.
3. Eyupoglu IY, Hahnen E, Buslei R, Siebzehnrubl FA, Savaskan NE, Luders M, et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005;93:992-9. (Pubitemid 40695758)
4. Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, et al. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 2007;83:267-75. (Pubitemid 46952237)
5. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007;13:1045-52. (Pubitemid 46340384)
6. An Z, Gluck CB, Choy ML, Kaufman LJ. Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Lett 2010;292:215-27.
7. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27:2052-8.
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
10. Wen P, Puduvalli VK, Kuhn J, Reid JM, Cloughesy T, Yung WK, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03). J Clin Oncol 2007;25:abstr 2039.
11. Schold SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro Oncol 2000;2:34-9.
12. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2006;840:108-15. (Pubitemid 44163473)
13. Xu J, Sampath D, Lang FF, Prabhu S, Rao G, Fuller GN, et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 2011;105:241-51.
14. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-100. (Pubitemid 27319755)